News

Innovative COVID-19 Vaccine Data Revealed by IMUNON's Study

Innovative COVID-19 Vaccine Data Revealed by IMUNON's Study

IMUNON Showcases Exciting New Data from COVID-19 Vaccine Trial

IMUNON, Inc. (NASDAQ: IMNN), a pioneering clinical-stage biotechnology firm based in Lawrenceville, has unveiled remarkable findings regarding its investigational DNA vaccine, IMNN-101. This informative update significantly contributes to the understanding of immunogenicity among COVID-19 variants, particularly focusing on the Omicron XBB1.5 strain. During a Phase 1 clinical trial involving 24 healthy participants, IMNN-101 displayed impressive safety and tolerability profiles, paving the way for further advancements in COVID-19 vaccination strategies.

Immunogenicity and Safety Profile of IMNN-101

The results from the Phase 1 proof-of-concept study showcased a notable 2- to 4-fold surge in neutralizing antibody (NAb) titers, following a single dose of IMNN-101. This increase was measured from baseline up to Week 4, with evidence of continued enhancement in immune response against the XBB1.5 variant. Importantly, these developments indicate the cross-reactivity of IMNN-101, illustrating potential effectiveness against multiple emerging variants.

Strong Support from IMUNON's Leadership

Stacy Lindborg, Ph.D., the CEO of IMUNON, expressed confidence in the data, stating, “Our findings demonstrate that IMNN-101 is both safe and immunogenic. These results show great promise for future vaccine development, especially considering the potential durability of protection and the stability of our vaccine at standard temperatures.” Lindborg highlighted the goal of seeking partnerships to enhance the developmental phase of this vaccine.

Examination of Baseline Immune Characteristics

Participants in the trial exhibited high baseline immune profiles, largely attributed to previous vaccinations and infections related to COVID-19. This background potentially impacted the observed T cell responses, which were noted to have increased following vaccination. Ai-ris Collier, M.D., Co-Director at the Center for Virology and Vaccine Research, praised the quality of the immunogenicity data, emphasizing the convincing immune response generated by IMNN-101 in trial participants.

The Foundation of PlaCCine Technology

IMNN-101 is primarily built on the innovative PlaCCine technology platform, which employs a unique DNA plasmid to facilitate effective expression of key pathogen antigens. This advanced delivery system is essential for enhancing manufacturing flexibility and ensuring the stability of the vaccine. The significant results from preclinical studies, demonstrating over 95% protection efficacy in non-human primates, reinforce the promising future of IMNN-101 and PlaCCine technology.

Details on the Phase 1 Clinical Trial

This Phase 1 study was executed across various settings, treating participants at DM Clinical Research and meticulously assessing safety and tolerability. Participants were separated into groups receiving escalating doses of the vaccine to establish optimal responses. The primary goals revolved around gauging the effectiveness of IMNN-101 in eliciting neutralizing antibody and cellular responses over time.

IMUNON's Commitment to Innovative Treatment Development

As a clinical-stage biotechnology company, IMUNON is ardently dedicated to creating advanced treatments that leverage the body’s immune mechanisms. Their approach marks a significant departure from traditional therapies. With a portfolio featuring the TheraPlas® modality for cytokine production and the PlaCCine® modality targeting infectious diseases, IMUNON is well-positioned to address unmet medical needs effectively.

The Future of IMNN-001 and COVID-19 Vaccination Efforts

IMUNON’s flagship program, IMNN-001, is currently progressing in Phase 2 trials, targeting localized treatments for advanced ovarian cancer. This therapy is designed to empower the body to generate enduring levels of cancer-fighting substances at the site of tumors. IMUNON remains committed to pushing the technological boundaries of plasmid DNA, ensuring that they provide better options for patients facing challenging conditions.

Frequently Asked Questions

What is IMUNON's primary focus?

IMUNON primarily focuses on developing non-viral DNA-mediated immunotherapy solutions for various diseases, including COVID-19.

What was the aim of the Phase 1 trial for IMNN-101?

The aim was to evaluate the safety, tolerability, and immunogenicity of IMNN-101 as a potential vaccination against the SARS-CoV-2 Omicron variant.

How effective was the IMNN-101 vaccine in the trial?

IMNN-101 showed a 2- to 4-fold increase in neutralizing antibodies following vaccination, indicating strong immunogenicity.

Who conducted the clinical trial for IMNN-101?

The trial was conducted by DM Clinical Research, which treated the participants during the study.

What future developments can we expect from IMUNON?

IMUNON plans to advance the development of its various therapeutic modalities and explore partnerships to further enhance its vaccine and treatment offerings.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 343

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
DoGo Power Revamps Energy for Remote Indonesian Isle

Updated Category News Views 77

Bringing Light to Pagerungan Kecil Island These days, if you wander into the fishing communities of Pagerungan Kecil Island, the buzz isn't just from the daily catch. Residents are talking about power, and not the kind you get from a generator spluttering along—I'm talking about a brand-new energy storage system that’s turning the lights on in ways these folks have...

Continue Reading
Envision and Tsinghua Propel Climate Innovation at COP31

Updated Category News Views 34

Collaborating for a Greener Future On the bustling stage of COP31 in Antalya, Turkey, Envision Energy and Tsinghua University teamed up with the Global Alliance of Universities on Climate (GAUC) to showcase a bold agenda. Their focus transcends mere dialogue, pushing for actionable climate solutions anchored in technological innovation, academic synergy, and the dynamism...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 306

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Guangdong-US Trade: LED Screens, Beef & Trust Make Waves

Updated Category News Views 0

Guangdong's Economic Ballet with the U.S. Grab a cup of coffee, and let's unravel how Guangdong and the U.S. are tangoing their way through trade like nobody's business! Guangdong, the heavyweight champ for U.S.-China trade transactions, notched up a cool 685.27 billion yuan ($102 billion) in the first eight months of 2026. That's a healthy jump of 6.9% year on year, mind...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 635

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 110

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 119

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 89

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 184

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading

Top 5 Most Recently Viewed Articles

Cordance Medical Secures $8M Seed Funding for Brain Solutions

Updated Category News Views 235

Groundbreaking Seed Financing for Cordance Medical Cordance Medical, a leader in noninvasive focused ultrasound technology for treating brain diseases, has successfully completed an oversubscribed seed financing round. This milestone was highlighted by exceeding the initial $8 million target, with participation from both new and existing investors such as Shanda Grab...

Continue Reading
Man Group PLC Discloses Open Positions for Aviva PLC

Updated Category News Views 179

Man Group PLC Reports on Relevant Securities In a significant disclosure, Man Group PLC has announced its public opening position in relation to Aviva PLC, emphasizing transparency in its dealings concerning relevant securities. The regulations governing such disclosures necessitate comprehensive reporting, particularly when interests exceed 1% of the relevant securities....

Continue Reading
Baird Raises Griffon Corp Price Target to $92, Outperform Rating

Updated Category News Views 63

Baird Updates Griffon Corp's Stock Projection Baird has elevated its price target on shares of Griffon Corp (NYSE: GFF) from $84.00 to $92.00. This revision to the target price comes with a maintained Outperform rating, signaling strong confidence in the company's outlook. The analyst from Baird forecasts a gradual increase in Griffon's fiscal fourth-quarter financial...

Continue Reading
Experience SoCal Car Culture at SPARQ's LA Auto Show Exhibit

Updated Category News Views 316

SPARQ Returns to LA Auto Show with Exciting Exhibit California's automotive AI startup SPARQ is making waves by returning to the highly anticipated Los Angeles Auto Show this November. This year, visitors can expect an immersive experience inside the Concourse Hall, showcasing an impressive lineup of hypercars, Formula 1 vehicles, and famous cars from iconic films such as...

Continue Reading
Sagent Behavioral Health: A New Era for Mental Wellness Providers

Updated Category News Views 616

Sagent Behavioral Health: Transforming Behavioral Healthcare Sagent Behavioral Health marks a significant advancement in the provision of mental health services in the Midwest. With the consolidation of Nystrom & Associates and its affiliated brands, including Ellie Mental Health, LifeWorks, and several others, this new entity aims to create a unified and robust network...

Continue Reading